Research
Hormonal
Semaglutide reduces cardiovascular risk (MACE) and non-ASCVD deaths (including from infections) in overweight/obese patients with established cardiovascular disease, independent of diabetes status.
If you are overweight or obese and have heart disease, semaglutide 2.4mg weekly can reduce your risk of heart attack, stroke, and death by 20%, even if you don't have diabetes. It may also reduce death from infections.
StrongSupportsHIGH confidence
Semaglutide also showed a 20% reduction in MACE in overweight or obese adults with preexisting ASCVD but without diabetes, according to the Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity (SELECT) trial... patients treated with semaglutide 2.4 mg presented a significant reduction in non-ASCVD deaths, especially deaths from infections.
Why this rating
Based on the SELECT trial, a major clinical trial with robust human data.
Source
Spotlight on the Mechanism of Action of Semaglutide
Ilias Papakonstantinou et al. · Current Issues in Molecular Biology · 2024
narrative_reviewCited 42×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →